Safety and Efficacy of HMI-103 in Participants With Classical PKU Due to PAH Deficiency

Stopped early · Phase 1

Conditions studied: Phenylketonurias, PAH Deficiency, Phenylketonuria

In brief

This is an open-label, sequential ascending dose-escalation, Phase 1 study to evaluate the safety and efficacy of a single intravenous (I.V.) administration of HMI-103, a gene editing development candidate, in adult participants aged 18 to 55 years, inclusive, with classical PKU due to PAH deficiency who have uncontrolled disease despite Phe restricted dietary management.

Key facts

Study ID
NCT05222178
Run by
Homology Medicines, Inc
People needed
3
Starts
2022-06-03
Expected to finish
2023-09-14
Last updated by the study team
2023-10-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.